CGRP Migraine Drugs Also Reduce Oxidative Stress Biomarkers in Treatment-Resistant Patients
CGRP inhibitors (erenumab, fremanezumab, galcanezumab) reduced oxidative stress biomarkers alongside dramatic migraine improvement in treatment-resistant patients, with 70% achieving ≥50% headache reduction by month 3.
Quick Facts
What This Study Found
CGRP inhibitors reduced AOPP (oxidative stress biomarker) over 6 months alongside 70% responder rates and significant improvements in disability, allodynia, fatigue, anxiety, and sleep quality in resistant migraineurs.
Key Numbers
70% 50% responders at 3 mo; ~25% 75% responders at 1 mo; AOPP decreased at 6 mo; allodynia moderate→mild; MIDAS improved
How They Did This
Real-world prospective study in tertiary headache center patients with high-frequency resistant migraine and medication overuse headache. Three CGRP mAbs used (erenumab, fremanezumab, galcanezumab). Oxidative stress biomarkers, headache frequency, MIDAS, allodynia, and comorbidity measures assessed at 3 and 6 months.
Why This Research Matters
Treatment-resistant migraine patients represent the greatest clinical challenge. Showing that CGRP inhibitors not only reduce headaches but also improve oxidative stress and multiple comorbidities supports their use as transformative therapies for the most difficult cases.
The Bigger Picture
The finding that CGRP inhibitors reduce oxidative stress adds a new dimension to understanding how these drugs work. Oxidative stress may be both a consequence and driver of chronic migraine, and its reduction could help explain the broad clinical improvements seen beyond simple headache frequency reduction.
What This Study Doesn't Tell Us
No control group. Real-world study without randomization or blinding. Small sample size implied. Oxidative stress is a biomarker with uncertain clinical significance in migraine.
Questions This Raises
- ?Is oxidative stress reduction a mechanism or consequence of migraine improvement?
- ?Could AOPP serve as a predictive biomarker for CGRP inhibitor response?
- ?Do the three CGRP antibodies differ in their oxidative stress-reducing effects?
Trust & Context
- Key Stat:
- 70% responder rate at 3 months In treatment-resistant migraine patients with medication overuse headache — among the most difficult cases to treat
- Evidence Grade:
- Prospective real-world study without control group. Provides practice-relevant effectiveness data with novel biomarker findings.
- Study Age:
- Published in 2021, from early real-world clinical experience with CGRP inhibitors in the most challenging migraine patients.
- Original Title:
- CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.
- Published In:
- Journal of clinical medicine, 10(19) (2021)
- Authors:
- De Luca, Ciro, Baldacci, Filippo, Mazzucchi, Sonia, Lombardo, Irene, Curto, Letizia, Ulivi, Martina, Chico, Lucia, Papa, Michele, Siciliano, Gabriele, Gori, Sara
- Database ID:
- RPEP-05334
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Do CGRP drugs work for the hardest-to-treat migraines?
Yes. In this study of patients with treatment-resistant migraine and medication overuse headache, 70% achieved at least 50% headache reduction within 3 months. Many also experienced improvements in sleep, anxiety, fatigue, and pain sensitivity.
What does oxidative stress have to do with migraines?
Oxidative stress — damage caused by unstable molecules called free radicals — may play a role in chronic migraine. This study found that CGRP inhibitors reduced a biomarker of oxidative stress (AOPP), suggesting these drugs may address an underlying biological process beyond just blocking pain signals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05334APA
De Luca, Ciro; Baldacci, Filippo; Mazzucchi, Sonia; Lombardo, Irene; Curto, Letizia; Ulivi, Martina; Chico, Lucia; Papa, Michele; Siciliano, Gabriele; Gori, Sara. (2021). CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.. Journal of clinical medicine, 10(19). https://doi.org/10.3390/jcm10194586
MLA
De Luca, Ciro, et al. "CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.." Journal of clinical medicine, 2021. https://doi.org/10.3390/jcm10194586
RethinkPeptides
RethinkPeptides Research Database. "CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant..." RPEP-05334. Retrieved from https://rethinkpeptides.com/research/de-2021-cgrp-inhibitors-and-oxidative
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.